Author's reply to: 'Prognostic value of cetuximab related skintoxicity in metastatic colorectal cancer patients and its correlation with parameters of the EGFR signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group'

摘要

We appreciate the critical remarks to our manuscript "Prognostic value of cetuximab related skin toxicity in metastatic colorectal cancer (mCRC) patients and its correlation with parameters of the EGFR signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group".As previously stated in our publication, patients treated with panitumumab in the PRIME study developing acneiform skin rash Grade >2 had longer progression-free survival (PFS) and overall survival (OS) compared to those with rash Grade 0-1. This observation was made in patients with KRAS wild-type and comparably also with KRAS-mutated tumors. Although, in fact, the numbers in our manuscript were quoted incorrectly, the underlying statement remains identical (Table 1)